Genome-wide expression profiling implicates a MAST3-regulated gene set in colonic mucosal inflammation of ulcerative colitis patients

Inflammatory Bowel Diseases

Volumn 18, Issue 6, 2012, Pages 1072-1080

  Labbé, Catherine ^a,b   Boucher, Gabrielle ^a   Foisy, Sylvain ^a   Alikashani, Azadeh ^a   Nkwimi, Herbert ^a   David, Geneviève ^a,b   Beaudoin, Mélissa ^a   Goyette, Philippe ^a   Charron, Guy ^a   Xavier, Ramnik J ^c   Rioux, John D ^a,b  

^a MONTREAL HEART INSTITUTE   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

inflammatory bowel disease; MAST3; NF B

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 3ALPHA; PROTEIN MD 2;

ARTICLE; CELL ADHESION; CELL LINE; CELL MIGRATION; COLON; CONTROLLED STUDY; GASTROINTESTINAL MUCOSA; GENE; GENE ACTIVITY; GENE EXPRESSION; GENE MAPPING; GENETIC ASSOCIATION; GENETIC REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNOREGULATION; INFLAMMATION; MACROPHAGE; MAST3 GENE; MUCOSA INFLAMMATION; PRIORITY JOURNAL; ULCERATIVE COLITIS;

BIOLOGICAL MARKERS; BLOTTING, WESTERN; COLITIS, ULCERATIVE; COLON; GENE EXPRESSION PROFILING; GENOME, HUMAN; HUMANS; IMMUNITY, MUCOSAL; MICROTUBULE-ASSOCIATED PROTEINS; MONOCYTES; MUCOSITIS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROTEIN-SERINE-THREONINE KINASES; REAL-TIME POLYMERASE CHAIN REACTION; RECTUM; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING;

EID: 84861336468     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.21887     Document Type: Article

References (35)

1. Khor B, Gardet A, Xavier RJ,. Genetics and pathogenesis of inflammatory bowel disease. Nature. 2011; 474: 307-317.
2. Anderson CA, Boucher G, Lees CW, et al. Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47. Nat Genet. 2011; 43: 246-252.
3. Franke A, McGovern DP, Barrett JC, et al. Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci. Nat Genet. 2011; 42: 1118-1125.
4. Labbe C, Goyette P, Lefebvre C, et al. MAST3: a novel IBD risk factor that modulates TLR4 signaling. Genes Immun. 2008; 9: 602-612.
5. Garland P, Quraishe S, French P, et al. Expression of the MAST family of serine/threonine kinases. Brain Res. 2008; 1195: 12-19.
6. Xiong H, Li H, Chen Y, et al. Interaction of TRAF6 with MAST205 regulates NF-kappaB activation and MAST205 stability. J Biol Chem. 2004; 279: 43675-43683.
7. Gentleman RC, Carey VJ, Bates DM, et al. Bioconductor: open software development for computational biology and bioinformatics. Genome Biol. 2004; 5: R80.
8. Du P, Kibbe WA, Lin SM,. Lumi: a pipeline for processing Illumina microarray. Bioinformatics. 2008; 24: 1547-1548.
9. Saeed AI, Bhagabati NK, Braisted JC, et al. TM4 microarray software suite. Methods Enzymol. 2006; 411: 134-193.
10. Huang da W, Sherman BT, Lempicki RA,. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009; 4: 44-57.
11. Bolstad BM, Irizarry RA, Astrand M, et al. A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics. 2003; 19: 185-193.
12. Gautier L, Cope L, Bolstad BM, et al. Affy-analysis of Affymetrix GeneChip data at the probe level. Bioinformatics. 2004; 20: 307-315.
13. Ito T, Carson WFT, Cavassani KA, et al. CCR6 as a mediator of immunity in the lung and gut. Exp Cell Res. 2011; 317: 613-619.
14. Daig R, Andus T, Aschenbrenner E, et al. Increased interleukin 8 expression in the colon mucosa of patients with inflammatory bowel disease. Gut. 1996; 38: 216-222.
15. Hugot JP, Chamaillard M, Zouali H, et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature. 2001; 411: 599-603.
16. Li J, Moran T, Swanson E, et al. Regulation of IL-8 and IL-1beta expression in Crohn's disease associated NOD2/CARD15 mutations. Hum Mol Genet. 2004; 13: 1715-1725.
17. Ferreiro DU, Komives EA,. Molecular mechanisms of system control of NF-kappaB signaling by IkappaBalpha. Biochemistry. 2010; 49: 1560-1567.
18. Heyninck K, Beyaert R,. The cytokine-inducible zinc finger protein A20 inhibits IL-1-induced NF-kappaB activation at the level of TRAF6. FEBS Lett. 1999; 442: 147-150.
19. O'Reilly SM, Moynagh PN,. Regulation of Toll-like receptor 4 signalling by A20 zinc finger protein. Biochem Biophys Res Commun. 2003; 303: 586-593.
20. Park BS, Song DH, Kim HM, et al. The structural basis of lipopolysaccharide recognition by the TLR4-MD-2 complex. Nature. 2009; 458: 1191-1195.
21. Arlt A, Rosenstiel P, Kruse ML, et al. IEX-1 directly interferes with RelA/p65 dependent transactivation and regulation of apoptosis. Biochim Biophys Acta. 2008; 1783: 941-952.
22. Billmann-Born S, Till A, Arlt A, et al. Genome-wide expression profiling identifies an impairment of negative feedback signals in the Crohn's disease-associated NOD2 variant L1007fsinsC. J Immunol. 2011; 186: 4027-4038.
23. Kobayashi KS, Chamaillard M, Ogura Y, et al. Nod2-dependent regulation of innate and adaptive immunity in the intestinal tract. Science. 2005; 307: 731-734.
24. Barrett JC, Hansoul S, Nicolae DL, et al. Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease. Nat Genet. 2008; 40: 955-962.
25. Braegger CP, Nicholls S, Murch SH, et al. Tumour necrosis factor alpha in stool as a marker of intestinal inflammation. Lancet. 1992; 339: 89-91.
26. Reinecker HC, Steffen M, Witthoeft T, et al. Enhanced secretion of tumour necrosis factor-alpha, IL-6, and IL-1 beta by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn's disease. Clin Exp Immunol. 1993; 94: 174-181.
27. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet. 2002; 359: 1541-1549.
28. Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med. 2004; 350: 876-885.
29. Lichtenstein GR, Bala M, Han C, et al. Infliximab improves quality of life in patients with Crohn's disease. Inflamm Bowel Dis. 2002; 8: 237-243.
30. Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med. 1997; 337: 1029-1035.
31. Jiang D, Chen Y, Schwarz H,. CD137 induces proliferation of murine hematopoietic progenitor cells and differentiation to macrophages. J Immunol. 2008; 181: 3923-3932.
32. Halstead ES, Mueller YM, Altman JD, et al. In vivo stimulation of CD137 broadens primary antiviral CD8+ T cell responses. Nat Immunol. 2002; 3: 536-541.
33. Arch RH, Thompson CB,. 4-1BB and Ox40 are members of a tumor necrosis factor (TNF)-nerve growth factor receptor subfamily that bind TNF receptor-associated factors and activate nuclear factor kappaB. Mol Cell Biol. 1998; 18: 558-565.
34. Lim HW, Lee J, Hillsamer P, et al. Human Th17 cells share major trafficking receptors with both polarized effector T cells and FOXP3+ regulatory T cells. J Immunol. 2008; 180: 122-129.
35. Brand S,. Crohn's disease: Th1, Th17 or both? The change of a paradigm: new immunological and genetic insights implicate Th17 cells in the pathogenesis of Crohn's disease. Gut. 2009; 58: 1152-1167.